Taipei, Feb. 10 (CNA) Over 5 million doses of vaccine developed by American pharmaceutical company Moderna Inc. are expected to be delivered to Taiwan between May and June, the country's Central Epidemic Command Center (CECC) said Wednesday, after Moderna announced a supply agreement with the Taiwan government.
Share this article
Share this article
DALLAS, Feb. 2, 2021 /PRNewswire/ COVAXX, a U.S. biotechnology company and subsidiary of United Biomedical, Inc. (UBI), has announced that the Taiwan Ministry of Health and Welfare on January 29, granted conditional approval to begin Phase 2 trials of UB-612, its vaccine candidate to address the pandemic caused by SARS-CoV-2. COVAXX is developing world s first multitope peptide-based vaccine against COVID-19, using its high precision, commercially proven and scalable vaccine platform.
The Phase 2 clinical trial is a multi-center, placebo-controlled, randomized, observer-blind study to further explore the immunogenicity, safety, and tolerability of the UB-612 vaccine in three distinctive cohorts: adolescents (12 to 18 years old), adults (19 to 64 years old), and seniors (65 years and older). The first subject of the Phase 2 trials was enrolled last week, with the goal of completing enrollment and administration of the first doses of UB-612
CECC reports four new imported COVID-19 cases taipeitimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taipeitimes.com Daily Mail and Mail on Sunday newspapers.
In the pipeline: What the next wave of COVID-19 vaccines could look like We take a look at some of the COVID-19 vaccine candidates moving through Phase 1 and 2 clinical trials - and how they could offer a point of difference to authorized vaccines.
While vaccines from big names such as Pfizer/BioNTech, Moderna and AstraZeneca are rolling out across the world, there are currently 64 vaccines in clinical development, according to the latest figures from the World Health Organization.
Phase 3 candidates from companies such as Johnson & Johnson and Curevac are well-known, but we take a look at some of the earlier-stage candidates coming through the pipeline.